Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
LUNGthis companyPulmonx Corporation	$2.81	-1.66×	1.66×	0.99×	-1.55×	-443.3%	74.2%	-59.3%	-59.7%	-99.8%	-48.5%	-36.6%	1.04×	0.28×	-17.01×	5.07×	0.0%	3	-5.79	2	C+
ACRVAcrivon Therapeutics, Inc. Common Stock	$1.64	-1.19×	0.82×	0×	-0.71×	-40.7%	0.0%	0.0%	0.0%	-69.2%	-73.0%	-70.4%	0.02×	0.51×	0×	7.69×	0.0%	1	-2.78	3	B-
HYPRHyperfine, Inc.	$0.71	-2.28×	2.25×	6.8×	-1.67×	-270.1%	49.8%	-273.4%	-262.3%	-86.8%	-84.7%	-31.6%	0.01×	1.01×	0×	4.34×	0.0%	4	-6.81	1	C-
IMUXImmunic, Inc.	$8.02	-0.86×	-12.46×	0×	-0.7×	-91.8%	0.0%	0.0%	0.0%	1456.2%	1693.4%	-103.4%	-0.1×	0.15×	0×	0.75×	0.0%	2	-5.39	2	C
PMVPPMV Pharmaceuticals, Inc.	$1.28	-0.84×	0.63×	0×	-0.36×	-52.3%	0.0%	0.0%	0.0%	-74.2%	-79.5%	-112.1%	0.01×	0.47×	0×	10.09×	0.0%	1	-6.12	3	B-
RLMDRelmada Therapeutics, Inc.	$4.12	-3.33×	2.2×	0×	-3.26×	-98.7%	0.0%	0.0%	0.0%	-66.3%	-67.5%	-24.0%	0×	0.06×	0×	14.62×	0.0%	2	13.25	1	C-
Peer median	—	-1.19×	0.82×	0×	-0.71×	-91.8%	0.0%	0.0%	0.0%	-69.2%	-73.0%	-70.4%	0.01×	0.47×	0×	7.69×	0.0%	2	-5.39	2	—